PT-141 (Bremelanotide) and Levothyroxine Interaction: What Every Woman Needs to Know

Why This Interaction Exists: The Mechanism in Plain Language

The interaction between bremelanotide and levothyroxine is not driven by cytochrome P450 enzymes or P-glycoprotein. Both drugs interact at the level of gastrointestinal physiology, and understanding that distinction matters for how you time your doses.

How levothyroxine is absorbed

Levothyroxine (L-T4) is absorbed almost exclusively in the small intestine, with bioavailability ranging from 60 to 80 percent in fasting adults. That number drops sharply when gastric motility slows, gastric pH rises, or other drugs or foods compete for the same intestinal transporters. Levothyroxine absorption is exquisitely sensitive to anything that alters gut transit time or luminal pH. This is why your prescriber instructs you to take it on an empty stomach, alone, 30-60 minutes before food.

What bremelanotide does to the gut

Bremelanotide is a synthetic cyclic heptapeptide that acts as a non-selective melanocortin receptor agonist, binding MC1R, MC3R, MC4R, and MC5R. MC4R activation in the central nervous system is responsible for its pro-sexual effect, but MC4R also exists in the gastrointestinal tract. MC4R stimulation slows gastric emptying and reduces gastrointestinal motility, which is the physiological basis for nausea, one of the most commonly reported adverse effects in the RECONNECT trials.

When gastric emptying slows, levothyroxine that is still in the stomach takes longer to reach the small intestinal absorptive surface. The result: reduced peak concentration (Cmax) and reduced total absorption (AUC) of levothyroxine for that dose. Over days to weeks of use, this can shift a well-controlled TSH into the under-replaced range.

CYP and P-gp: not involved here

Neither bremelanotide nor levothyroxine is a meaningful CYP substrate, inhibitor, or inducer at clinical doses. The FDA label for Vyleesi (bremelanotide) identifies slowed gastric emptying as the primary drug interaction concern and explicitly calls out the risk with orally administered drugs that have narrow therapeutic indices. Levothyroxine has a narrow therapeutic index. That combination is exactly why timing matters.

How Significant Is This Interaction? A Clinical Severity Assessment

Regulatory drug interaction databases classify this combination as moderate severity, meaning it is clinically significant but manageable without permanently avoiding one drug. The word "moderate" can feel reassuring, but for a woman on thyroid hormone suppression therapy after thyroid cancer, even a 10-15 percent reduction in levothyroxine absorption across multiple doses can push TSH above the suppression target and, in theory, stimulate residual thyroid tissue.

Women most at risk

The interaction carries the greatest clinical weight in three groups:

• Women on suppressive levothyroxine dosing after differentiated thyroid cancer, where TSH targets may be as low as 0.1-0.5 mIU/L. Any absorption loss has a narrower margin of safety.
• Women with Hashimoto's thyroiditis who are already on doses calibrated to the low end of replacement, where small shifts translate directly into hypothyroid symptoms.
• Perimenopausal women whose thyroid requirements fluctuate alongside estrogen levels. Estrogen increases thyroid-binding globulin (TBG), so as estrogen drops in perimenopause, free T4 availability shifts even without any drug interaction adding complexity.

Women at lower risk

A woman using PT-141 occasionally (bremelanotide is labeled for use no more than once per 24 hours and no more than eight times per month per the Vyleesi prescribing information) who consistently separates her levothyroxine dose by four or more hours will likely see no measurable effect on her TSH.

Life-Stage Considerations: How Thyroid Status and Sexual Function Intersect

Reproductive years

In your reproductive years, untreated or under-treated hypothyroidism directly impairs sexual function. Thyroid hormone deficiency reduces sex hormone-binding globulin (SHBG), suppresses ovarian steroidogenesis, and lowers testosterone and estradiol levels, all of which contribute to low sexual desire. If you are using PT-141 for hypoactive sexual desire disorder (HSDD) and your levothyroxine is being inadvertently under-absorbed, you may be treating a symptom that is partly self-induced by the drug timing problem. Fix the timing first, recheck TSH, and reassess whether your desire symptoms improve before attributing everything to HSDD.

Perimenopause

Perimenopause is when thyroid and sexual dysfunction most commonly overlap. Up to 47 percent of perimenopausal women report low sexual desire, and thyroid disease prevalence in women peaks in this same life stage. PT-141 is FDA-approved only for premenopausal women, but clinicians do use it off-label in perimenopausal patients. If you are perimenopausal and on levothyroxine, your prescriber should be aware that your TBG is already declining as estrogen falls. Adding an intermittent absorption disruptor like bremelanotide makes TSH monitoring even more important.

Post-menopause

Post-menopause brings persistently lower TBG and often lower levothyroxine requirements compared to premenopausal dosing. Bremelanotide has not been studied in postmenopausal women in the context of thyroid hormone, and the FDA approval does not extend to this group. The interaction mechanism is the same, but the clinical context of off-label use means less data to guide you.

The FDA-Approved Indication: Who PT-141 Is Actually For

Bremelanotide (Vyleesi) received FDA approval in June 2019 for the treatment of HSDD in premenopausal women. The approval was based on two phase 3 randomized controlled trials, RECONNECT Study 1 and RECONNECT Study 2, published in the Journal of Sexual Medicine. In the pooled trials, women using bremelanotide 1.75 mg subcutaneously showed statistically significant improvements in desire and reductions in distress scores versus placebo over 24 weeks.

HSDD is defined by persistently low sexual desire that causes personal distress. The diagnosis requires ruling out contributing medical causes, which is where thyroid function enters the picture. Under-replaced hypothyroidism is on the differential for low libido, and your prescriber should have obtained a TSH before initiating PT-141.

Practical Dosing and Timing Guide

This is where the clinical instruction becomes concrete.

The four-hour rule

Take your levothyroxine first thing in the morning, on an empty stomach, 30-60 minutes before breakfast. If you are planning to use PT-141 that day, wait at least four hours after your levothyroxine dose before injecting bremelanotide. By that point, levothyroxine absorption from the proximal small intestine is essentially complete, and bremelanotide's effect on gastric emptying will have no meaningful impact on that dose.

Do not skip levothyroxine on days you use PT-141

Skipping your thyroid dose to avoid the interaction creates a larger problem than timing it correctly. A single missed levothyroxine dose causes a measurable TSH rise within days in women with no residual thyroid function.

What to do if you forget the timing

If you took your levothyroxine and PT-141 within the same two-hour window, do not double your next levothyroxine dose. Take your next scheduled levothyroxine dose at the usual time the following morning. If this mismatch happens repeatedly, notify your prescriber so they can order a TSH check.

Injection timing around meals

Bremelanotide itself does not need to be taken on an empty stomach. The prescribing information recommends injecting approximately 45 minutes before anticipated sexual activity. Its own absorption is subcutaneous and unaffected by food.

Other Levothyroxine Interactions You Should Know About

Given that women on levothyroxine often take multiple medications, it is worth placing the bremelanotide interaction in the context of the broader levothyroxine absorption problem.

Several drug classes reduce levothyroxine absorption, including:

• Calcium carbonate (interfere even four hours apart in some patients)
• Proton pump inhibitors (raise gastric pH, reduce dissolution)
• Cholestyramine and colestipol (bind T4 in the gut)
• Ferrous sulfate (chelation in the intestinal lumen)
• Antacids containing aluminum or magnesium

Bremelanotide operates via a different mechanism (motility reduction rather than pH change or direct binding), but the net effect on absorption is comparable in principle. The four-hour separation rule that applies to most of these substances applies to bremelanotide as well.

Pregnancy, Lactation, and Contraception

This section is required reading if you are trying to conceive, are pregnant, or are breastfeeding.

Bremelanotide in pregnancy

Bremelanotide is contraindicated in pregnancy. The FDA label carries a specific warning: bremelanotide caused fetal harm in animal reproduction studies, including reduced fetal weight and increased implantation loss at doses below the human therapeutic exposure. No adequate human pregnancy data exist. If you become pregnant while using PT-141, stop the drug immediately and contact your obstetrician.

Because of this teratogenic signal, you must use effective contraception throughout bremelanotide treatment. The FDA label does not specify a washout period after discontinuation before attempting conception, but given bremelanotide's half-life of approximately 2.7 hours, the drug itself clears within 24 hours. The animal data concern relates to exposure during organogenesis, so avoiding use once a pregnancy is confirmed is the key step.

Levothyroxine in pregnancy

Levothyroxine, by contrast, is not only safe in pregnancy but is actively required for fetal neurological development during the first trimester, when the fetus cannot yet produce its own thyroid hormone. Untreated hypothyroidism in pregnancy is associated with preterm birth, placental abruption, and impaired fetal neurodevelopment. Levothyroxine requirements increase by approximately 25-50 percent during pregnancy, and your dose should be adjusted as soon as pregnancy is confirmed. The American Thyroid Association 2017 guidelines recommend TSH targets of <2.5 mIU/L in the first trimester.

The practical implication: If you are on levothyroxine, trying to conceive, and considering PT-141, stop bremelanotide before attempting conception and ensure your TSH is optimized before pregnancy. A TSH in the upper half of the reference range before conception is already a risk factor for miscarriage.

Bremelanotide and lactation

No human data exist on bremelanotide transfer into breast milk. Animal studies detected bremelanotide in milk. The FDA label advises against use during breastfeeding. Levothyroxine, by contrast, transfers into breast milk only in tiny amounts and is considered compatible with breastfeeding by the American Academy of Pediatrics.

Who This Combination Is Right For, and Who Should Proceed Carefully

Reasonable candidates

You are a reasonable candidate for using both drugs simultaneously if:

• Your hypothyroidism is well-controlled (TSH within your personal target range in the last 3-6 months)
• You are premenopausal and meet criteria for HSDD
• You can consistently separate your levothyroxine and bremelanotide doses by four or more hours
• Your prescriber knows you are on both medications

Proceed with extra caution if:

• You are on thyroid cancer suppression therapy with a TSH target below 0.5 mIU/L
• Your TSH has been erratic in recent months without a clear cause (the interaction could be a factor you have not yet identified)
• You are perimenopausal and your levothyroxine dose has needed recent adjustment
• You take other levothyroxine-absorption disruptors in the same window

This combination is not appropriate if:

• You are pregnant or planning pregnancy in the near term
• You are breastfeeding
• You have uncontrolled hypertension: bremelanotide causes a transient blood pressure rise (mean increase of approximately 6 mmHg systolic and 3 mmHg diastolic lasting up to 12 hours after dosing), and this is an independent contraindication unrelated to the levothyroxine interaction

Monitoring Plan: What Labs You Need and When

A structured monitoring plan removes guesswork and protects your thyroid replacement.

Baseline

Before starting bremelanotide, obtain a TSH (and free T4 if your TSH has been unstable). Document it. This gives you a reference point.

After starting PT-141

Recheck TSH 6-8 weeks after you begin using bremelanotide regularly. TSH has a half-life of approximately one week, and the pituitary response to a change in circulating T4 takes several weeks to fully reflect in a TSH value. An 8-week recheck captures any absorption-related drift.

If TSH is elevated on recheck

Work through the timing issue first before your prescriber increases your levothyroxine dose. Ask yourself honestly: have you been taking levothyroxine and bremelanotide within two hours of each other? Correcting the timing and rechecking TSH in another 6-8 weeks is the first step, not automatically increasing the levothyroxine dose. Adding dose on top of a timing problem risks over-replacement once the timing is corrected.

Annual monitoring

TSH should be checked at least annually regardless of bremelanotide use, per standard thyroid monitoring guidelines.

What to Tell Your Prescribers

Many women see separate providers for their thyroid and for sexual health. These two conversations need to happen in the same room, or at least in the same chart.

Tell your thyroid prescriber: "I am using or considering bremelanotide (Vyleesi or PT-141) for low sexual desire. I understand it can slow gastric emptying. I want to make sure we are checking my TSH at the right intervals and that you know about this."

Tell your sexual health prescriber: "I take levothyroxine every morning. I know bremelanotide can affect thyroid hormone absorption if I don't time it correctly. Please note my thyroid condition in my chart."

A note on the evidence gap: no published pharmacokinetic study has directly measured levothyroxine AUC or Cmax when co-administered with bremelanotide in women. The interaction is inferred from bremelanotide's known effect on gastric motility and from the well-established sensitivity of levothyroxine absorption to motility changes. The RECONNECT trial protocol excluded women with uncontrolled thyroid disease, which means this population was not studied. Women on stable thyroid replacement were not explicitly excluded, but thyroid hormone levels were not measured as a study endpoint. This gap in the trial design means the clinical guidance above is based on mechanistic reasoning and levothyroxine pharmacokinetics literature, not a head-to-head interaction study. Your prescriber should know that.

Nausea Management: Practical Advice That Protects Your Levothyroxine

Up to 40 percent of women using bremelanotide experience nausea, which is the most common adverse effect. Some women take an antiemetic to manage it. Here is why this matters for your levothyroxine:

• Ondansetron (Zofran), the most commonly used antiemetic for bremelanotide nausea, has no significant interaction with levothyroxine.
• Metoclopramide, occasionally used for nausea, actually increases gastric motility and could theoretically offset bremelanotide's gastroparetic effect, but its use requires a separate clinical discussion given its own risk profile.
• Avoid antacids taken close to your levothyroxine dose, since nausea from bremelanotide might tempt you to reach for an antacid in the morning. Calcium- or magnesium-based antacids reduce levothyroxine absorption independently of bremelanotide.

The safest approach: use bremelanotide in the evening or afternoon, well after your morning levothyroxine has been absorbed. This spacing addresses both the absorption interaction and places any nausea in a part of your day when it is less new.